ProQR Therapeutics BV (PRQR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has a cash flow conversion efficiency ratio of -0.156x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.40 Million) by net assets ($79.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ProQR Therapeutics BV stock valuation for the company's overall valuation and market capitalisation.
ProQR Therapeutics BV - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how ProQR Therapeutics BV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ProQR Therapeutics BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProQR Therapeutics BV ranked by their cash flow conversion efficiency. Explore ProQR Therapeutics BV cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cosmo Chem
KO:005420
|
0.086x |
|
HAXC Holdings (Beijing) Co. Ltd.
SHE:300928
|
N/A |
|
Humble Group AB
ST:HUMBLE
|
0.037x |
|
Jiangsu Huaxin New Material Co Ltd Class A
SHE:300717
|
0.035x |
|
SC Asset Corporation Public Company Limited
BK:SC
|
-0.012x |
|
Beetaloo Energy Australia Limited
AU:BTL
|
-0.055x |
|
Batavia Prosperindo Int
JK:BPII
|
0.016x |
|
Fiera Capital Corporation
TO:FSZ
|
0.138x |
Annual Cash Flow Conversion Efficiency for ProQR Therapeutics BV (2013–2025)
The table below shows the annual cash flow conversion efficiency of ProQR Therapeutics BV from 2013 to 2025. View PRQR live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.99 Million | $-52.79 Million | -0.910x | -129.40% |
| 2024-12-31 | $91.70 Million | $-36.39 Million | -0.397x | -184.21% |
| 2023-12-31 | $45.72 Million | $21.55 Million | 0.471x | +148.96% |
| 2022-12-31 | $71.17 Million | $-68.51 Million | -0.963x | -376.53% |
| 2021-12-31 | $128.76 Million | $-26.01 Million | -0.202x | +70.30% |
| 2020-12-31 | $69.19 Million | $-47.06 Million | -0.680x | -62.93% |
| 2019-12-31 | $105.33 Million | $-43.97 Million | -0.417x | -26.11% |
| 2018-12-31 | $92.69 Million | $-30.68 Million | -0.331x | +55.27% |
| 2017-12-31 | $47.22 Million | $-34.95 Million | -0.740x | -21.22% |
| 2016-12-31 | $56.05 Million | $-34.22 Million | -0.611x | -145.80% |
| 2015-12-31 | $97.55 Million | $-24.23 Million | -0.248x | -127.47% |
| 2014-12-31 | $132.38 Million | $-14.46 Million | -0.109x | -100.57% |
| 2013-12-31 | $-122.64K | $-2.33 Million | 19.015x | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more